What is Decree No. 225 / 2005 Coll.?

Decree No. 225 / 2005 Coll., amending Decree No. 589 / 2004 Coll., on the reimbursement of medicines and foodstuffs for special medical purposes — Decree amending Decree No. 589 / 2004 Coll., on the reimbursement of medicines and foodstuffs for special medical purposes.

When it became Decree No. 225 / 2005 Coll. effectiveness?

Decree No. 225 / 2005 Coll. became effective 01.07.2005.

Is Decree No. 225 / 2005 Coll. still valid?

Yes, Decree No. 225 / 2005 Coll. is still valid and effective.

How many times was it Decree No. 225 / 2005 Coll. amended?

Decree No. 225 / 2005 Coll. has 3 time versions of the text.

Decree No. 225 / 2005 Coll.

Decree amending Decree No. 589 / 2004 Coll., on the reimbursement of medicines and foodstuffs for special medical purposes

Valid Order Effective from 01.07.2005

Text versions: 01.07.2005 15.06.2005

Čl. I Čl. II Čl. III

Zobrazeno prvních 200 z celkem 1662 ustanovení tohoto předpisu. Zobrazit celý předpis →

Pro stažení celého znění použijte tlačítko Stáhnout výše.

225

DECLARATION

of 1 June 2005

amending Decree No 589 / 2004 Coll., on the reimbursement of medicines and foodstuffs for special medical purposes

According to Article 15 (10) of Act No. 48 / 1997 Coll., on Public Health Insurance, and amending and supplementing certain related laws, as amended by Act No. 438 / 2004 Coll., hereinafter referred to as "the Act":

Čl. I

Decree No 589 / 2004 Coll., on the reimbursement of medicinal products and foodstuffs for special medical purposes, is amended as follows:

1. Annex No 1 shall read as follows:

Příloha č.1

Annex No. 1 to Decree No 598 / 2004 Coll.

Medicinal products, including individually prepared medicinal products, radiopharmaceuticals and transfusion products, and food for special medical purposes fully covered by health insurance, the amount of payments of active substances and the amount of food payments for special medical purposes

Číslo řádku vyhlášky	Označení ATC a V06XX	Název léčivé látky		Cesta podání	Množství	Název jedn.	Úhrada v Kč

1		Stomatologika

1.1	A01AA01		fluorid sodný	p.o.	1.10	MG	0.88

46265	ZYMAFLUOR 1/4 MG	portblnob200x0.25mg	FAJ	I
64958	ZYMAFLUOR 1/4 MG	portblnob200x0.25mg	NCH	CH

1.2	A01AB10		natamycin	lok.	20.00	MG	7.48

1.3	A01AB03		chlorhexidin	lok.	1 000.00	ML	178.70	H

1.4	A01AC01		triamcinolon	lok.	1.00	GM	13.69	L/DER,STO, ORL

1.5	A01AC02		dexametason	lok.	1.00	GM	11.68	L/DER,STO, ORL

2		adsobční anatacida a protivředová léčiva ze skupiny H2-blokátorů, perorální podání

2.1	A02AD		kombinace hliníku, vápníku a hořčíku (pevné lékové formy)	p.o.	10.00	DF	3.40

2.2	A02AD		kombinace hliníku, vápníku a hořčíku (tekuté lékové formy)	p.o.	50.00	ML	3.40

2.3	A02AD01		kombinace hliníku, vápníku a hořčíku (obvyklé kombinace solí – pevné lékové formy)	p.o.	10.00	DF	3.40

2.4	A02AD01		kombinace hliníku, vápníku a hořčíku (obvyklé kombinace solí – tekuté lékové formy)	p.o.	50.00	ML	3.40

2.5	A02AD04		hydrotalcit (pevné lékové formy)	p.o.	10.00	DF	3.40

2.6	A02AD04		hydrotalcit (tekuté lékové formy)	p.o.	50.00	ML	3.40

2.7	A02BA01		cimetidin	p.o.	0.80	GM	3.40

2.8	A02BA02		ranitidin nad 75 mg v 1tbl	p.o.	0.30	GM	3.40

12346

HISTAC 150

tbl obd 20x150mg

RXY

IND

2.9

A02BA03

famotidin 20 mg a výše v 1 tabletě

p.o.

40.00

3.40

47863	FAMOSAN 40 MG	por tbl flm100x40mg	PMP	CZ
59596	FAMOSAN 40 MG	por tbl flm 50x40mg	PMP	CZ

2.10	A02BA04		nizatidin	p.o.	0.30	GM	3.40

2.11	A02BA06		roxatidin	p.o.	0.15	GM	3.40

2.12	A02BA07		ranitidin bismut citrát	p.o.	0.80	GM	28.50

3		protivředová léčiva ze skupiny inhibitorů protonové pumpy a ostatní protivředová léčiva

3.1	A02BA01		cimetidin	parent.	0.80	GM	32.06	H

3.2	A02BA02		ranitidin	parent.	0.30	GM	68.43	H

3.3	A02BA03		famotidin	parent.	40.00	MG	68.43	H

3.4	A02BB01		misoprostol	p.o.	0.80	MG	47.36	Z

3.5	A02BC01		omeprazol	parent.	20.00	MG	170.00	H

3.6	A02BC01		omeprazol (do 10 mg v jedné dávce včetně)	p.o.	20.00	MG	15.50

32174	OMERA 10	por cps etd 14x10mg	SLO	SK
32175	OMERA 10	por cps etd 28x10mg	SLO	SK

3.7

A02BC01

omeprazol (nad 10 mg v jedné dávce)

p.o.

20.00

9.28

98330	OMEPROL 20	por tbl ent 7x20mg	SFS	D
98331	OMEPROL 20	por tbl ent 14x20mg	SFS	D
98332	OMEPROL 20	por tbl ent 28x20mg	SFS	D
03076	LOMAC	cps 28x20mg	CIA	IND
03077	LOMAC	cps 56x20mg	CIA	IND
10245	OMEPRAZOL AL 20	por cps etd 30x20mg	APA	D
12507	GASEC-20	por cps dur 14x20mg	MHA	P
15555	APO-OME 20	por cps etd 14x20mg	CMG	IRL
15556	APO-OME 20	por cps etd 28x20mg	CMG	IRL
15558	APO-OME 20	por cps etd100x20mg	CMG	IRL
16003	LOMAC	por cps dur 14x20mg	SDD	CZ
16004	LOMAC	por cps dur 28x20mg	SDD	CZ
16005	LOMAC	por cps dur 56x20mg	SDD	CZ
17946	APO-OME 20	por cps etd 14x20mg	KAT	NL
17947	APO-OME 20	por cps etd 28x20mg	KAT	NL
17949	APO-OME 20	por cps etd100x20mg	KAT	NL
31511	OMEPIREX 20 MG	por cps etd 28x20mg	LOT	E
31512	OMEPIREX 20 MG	por cps etd 56x20mg	LOT	E
44060	APO-OME 20	por cps etd 14x20mg	APT	CND
44061	APO-OME 20	por cps etd 28x20mg	APT	CND
44063	APO-OME 20	por cps etd100x20mg	APT	CND
47473	GASEC-20	por cps dur 56x20mg	MHA	P
49747	APO-OME 20	por cps etd 14x20mg	TOP	CND
49748	APO-OME 20	por cps etd 28x20mg	TOP	CND
49750	APO-OME 20	por cps etd100x20mg	TOP	CND
53346	GASEC-20	por cps dur 28x20mg	MHA	P
56500	HELICID 20	cps 14x20mg	ZEH	CZ
58202	OMEPROL 20 MG	por cps etd 30x20mg	SFS	D
58203	OMEPROL 20 MG	por cps etd 60x20mg	SFS	D
58225	OMEPRAZOL-E	cps ent 14x20mg	EGI	H
58226	OMEPRAZOL-E	cps ent 28x20mg	EGI	H
59897	HELICID 20	cps 28x20mg	ZEH	CZ
60160	ULTOP	cps 14x20mg	KRK	SLO
70933	ORTANOL	por cps dur 28x20mg	LEK	SLO
75166	ORTANOL	por cps dur 14x20mg	LEK	SLO
75974	LOMAC	cps 14x20mg	CIA	IND
94361	OMEPROL 20 MG	por cps etd 30x20mg	IIS	TR
94362	OMEPROL 20 MG	por cps etd 60x20mg	IIS	TR
94476	OMEPROL 20 MG	por cps etd 14x20mg	SFS	D
94477	OMEPROL 20 MG	por cps etd 14x20mg	IIS	TR
94478	OMEPROL 20 MG	por cps etd 28x20mg	IIS	TR
94479	OMEPROL 20 MG	por cps etd 28x20mg	SFS	D
98625	OMEPRAZOL-RATIOPHARM 20 MG	por cps etd 15x20mg	MCK	D
98626	OMEPRAZOL-RATIOPHARM 20 MG	por cps etd 30x20mg	MCK	D

3.8	A02BC02	pantoprazol	p.o.	40.00	MG	9.50

3.9	A02BC02	pantoprazol	parent.	40.00	MG	170.00	H

3.10	A02BC03	lansoprazol	p.o.	30.00	MG	9.28

3.11	A02BC05	esomeprazol (do 20mg v jedné dávce včetně)	p.o.	20.00	MG	12.00	L/GIT,INT,GER

3.12	A02BC05	esomeprazol (nad 20mg v jedné dávce)	p.o.	20.00	MG	6.67	L/GIT,INT,GER

3.13	A02BX	ostatní léčiva peptického vředu (bismut subsalicylat)	p.o.	3.00	DF	22.29

3.14	A02BX02	sukralfát	p.o.	4.00	GM	9.28

91217

VENTER

tbl 50x1gm

KRK

SLO

3.15	A02BX03		pirenzepin	p.o.	0.10	GM	8.55

3.16	A02BX03		pirenzepin	parent.	20.00	MG	105.58	H

3.17	A02BX05		zásaditý citronan bismutitý	p.o.	0.48	GM	23.07

4		spasmolytika, perorální podání

4.1	A03AA04		mebeverin	p.o.	0.30	GM	4.94

4.2	A03AA05		trimebutin	p.o.	0.30	GM	4.94

4.3	A03AB03		oxyfenon	p.o.	25.00	MG	2.30

4.4	A03AB06		otilonium bromid	p.o.	0.12	GM	12.42

4.5	A03AB11		poldin	p.o.	12.00	MG	2.30

4.6	A03AD01		papaverin	p.o.	0.10	GM	0.68

4.7	A03AD02		drotaverin	p.o.	0.10	GM	4.88

4.8	A03BA01		atropin	p.o.	1.50	MG	0.49

4.9	A03BB01		butylskopolamin	p.o.	60.00	MG	14.21

01317

BUSCOPAN

por tbl obd 20x10mg

BOE

5		Spasmolytika, ostatní cesty aplikace

5.1	A03AD01		papaverin	parent.	0.10	GM	17.94

5.2	A03AD02		drotaverin	parent.	0.10	GM	25.55

02552

NO-SPA

inj 5x2ml/40mg

CHN

5.3	A03BA01		atropin (1 mg a více v 1 ampuli)	parent.	1.50	MG	7.83

5.4	A03BA01		atropin (do 1mg v 1 ampuli)	parent.	1.50	MG	15.15

5.5	A03BB01		butylskopolamin	p.rect.	60.00	MG	14.66

5.6	A03BB01		butylskopolamin	parent.	60.00	MG	37.62

6		anticholinergika a spasmolytika v kombinaci s analgetiky

6.1	A03DA		syntetická anticholinergika v komb. s analgetiky	p.o.	2.00	DF	3.96

6.2	A03DA02		pitofenon kombinace s analgetiky	p.rect.	2.00	DF	13.60

91517

ALGIFEN SUP

rct sup 5

LEX

6.3	A03DA02		pitofenon kombinace s analgetiky	parent.	2.00	DF	44.25

6.4	A03DA02		pitofenon kombinace s analgetiky (pevné lékové formy)	p.o.	2.00	DF	4.11

6.5	A03DA02		pitofenon kombinace s analgetiky (tekuté lékové formy)	p.o.	2.00	ML	5.82

6.6	A03EA		antispasmodika, psycholeptika, analgetika v komb.	p.rect.	2.00	DF	12.72

7		Prokinetika, antiflatulencia, perorální podání

7.1	A03AE02		tegaserod	p.o.	12.00	MG	30.00

7.2	A03AX13		silikony (pevné lékové formy)	p.o.	0.50	GM	10.91

7.3	A03AX13		silikony (tekuté lékové formy)	p.o.	0.50	GM	18.57

93500

SAB SIMPLEX

sus 1x30ml

PDA

7.4	A03AX58	alverin (kombinace se silikony)	p.o.	0.18	GM	7.90

7.5	A03FA	itoprid	p.o.	0.15	GM	26.60	L/GIT,INT,PED

7.6	A03FA01	metoclopramid hydrochlorid	p.o.	30.00	MG	3.96

56696	MCP HEXAL 10	tbl 100x10mg	SFS	D
96974	CERUCAL	por tbl nob 50x10mg	AWD	D

7.7	A03FA02		cisaprid (pevné lékové formy, nad 10 mg v 1 tabletě)	p.o.	30.00	MG	22.50		L/GIT,INT,PED, PSY, GER

7.8	A03FA02		cisaprid (pevné lékové formy, nad 5 mg do 10 mg včetně v 1 tabletě)	p.o.	30.00	MG	26.00		L/GIT,INT,PED, PSY, GER

7.9	A03FA02		cisaprid (tekuté lékové formy dělené -sáčky)	p.o.	30.00	MG	26.00		L/GIT,INT,PED, PSY, GER

7.10	A03FA02		cisaprid (tekuté lékové formy) s obsahem 1 mg v 1 ml	p.o.	30.00	MG	57.18		L/GIT,INT,PED, PSY, GER

7.11	A03FA03		domperidon	p.o.	30.00	MG	3.96

7.12	A03FA05		alizaprid	p.o.	0.15	GM	3.96

8		Prokinetika, ostatní cesty aplikace

8.1	A03FA01		metoclopramid	p.rect.	30.00	MG	41.50

8.2	A03FA01		metoclopramid	parent.	30.00	MG	21.28	O

93105

DEGAN

inj 50x2ml/10mg

LEK

SLO

8.3	A03FA02		cisaprid	p.rect.	30.00	MG	47.57

8.4	A03FA03		domperidon	p.rect.	0.12	GM	41.50

8.5	A03FA05		alizaprid	parent.	0.15	GM	16.47	O

9		antiemetika, perorální podání

9.1	A04AA01		ondansetron (pevné lékové formy do 4 mg v jedné tabletě včetně)	p.o.	16.00	MG	535.50	P

15829	EMESET- 4	por tbl flm 6x4mg	SDD	CZ
15830	EMESET- 4	por tbl flm 60x4mg	SDD	CZ
84744	EMESET- 4	tbl obd 6x4mg	CIA	IND
84794	EMESET- 4	tbl obd (10x6)x4mg	CIA	IND

9.2	A04AA01	ondansetron (pevné lékové formy nad 4 mg v jedné tabletě)	p.o.	16.00	MG	396.90	P

9.3	A04AA01	ondansetron (rychle rozpustné pevné lékové formy do 4 mg v jedné tabletě včetně)	p.o.	16.00	MG	562.30	P

9.4	A04AA01	ondansetron ((rychle rozpustné pevné lékové formy nad 4 mg v jedné tabletě)	p.o.	16.00	MG	416.70	P

9.5	A04AA01	ondansetron (tekuté lékové formy)	p.o.	16.00	MG	754.65	P

9.6	A04AA02	granisetron	p.o.	2.00	MG	396.90	P

9.7	A04AA03	tropisetron	p.o.	5.00	MG	396.90	P

9.8	A04AA04	dolasetron	p.o.	200.00	MG	396.90	P

Ondasetron, granisetron, tropisetron and dolasetron are indicated in patients with nausea and vomiting due to strong serotonin release, i. e. induced by cytotoxic chemotherapy and radiotherapy.

9.9	A04AD		různá antiemetika (meklozin)	p.o.	50.00	MG	3.31

9.10	A04AD		různá antiemetika (theoklát embraminu)	p.o.	50.00	MG	3.31

9.11	A04AD		různá antiemetika (theoklát moxastinu)	p.o.	0.10	GM	3.31

10		antiemetika, ostatní cesty aplikace

10.1	A04AA01		ondansetron (léková forma čípků)	p.rect.	16.00	MG	648.93	P

56742	ZOFRAN	sup 1x16mg	GWE	F
70533	ZOFRAN	sup 1x16mg	GWH	F

10.2

A04AA01

ondansetron (do 4 mg v jedné ampuli včetně)

parent.

16.00

895.70

84441	EMESET	inj 5x2ml/4mg	CIA	IND
15827	EMESET	inj sol 5x2ml/4mg	SDD	CZ

10.3	A04AA01	ondansetron (nad 4 mg v jedné ampuli)	parent.	16.00	MG	722.40	P

10.4	A04AA02	granisetron	parent.	3.00	MG	474.20	P

10.5	A04AA03	tropisetron (do 2,5 mg včetně v jedné ampuli)	parent.	5.00	MG	816.20	P

10.6	A04AA03	tropisetron (nad 2,5 mg v jedné ampuli)	parent.	5.00	MG	474.20	P

10.7	A04AA04	dolasetron	parent.	100.00	MG	474.20	P

Ondasetron, granisetron, tropisetron and dolasetron are indicated in patients with nausea and vomiting due to strong serotonin release, i. e. induced by cytotoxic chemotherapy and radiotherapy.

10.8	A04AD01		různá antiemetika (theoklát moxastinu)	p.rect.	0.10	GM	9.38

11		hepatika a hepatoprotektiva a další léčiva působící na žlučové cesty nebo játra

11.1	A05AA01		kyselina chenodeoxycholová	p.o.	1.00	GM	21.46	L/GIT,INF

11.2	A05AA02		kyselina ursodeoxycholová	p.o.	0.75	GM	23.74	L/GIT, INF

91017

URSOFALK

cps 100x250mg

FAK

11.3	A05AX	jiná léčiva onemocnění žlučníku (fenipentol)	p.o.	3.00	DF	1.62

11.4	A05AX02	hymekromon	p.o.	1.20	GM	5.96

11.5	A05BA	léčiva onemocnění jater (fosfolipidy)	p.o.	4.00	DF	11.73

11.6	A05BA	léčiva onemocnění jater (fosfolipidy)	parent.	1.00	DF	42.72	H

11.7	A05BA	léčiva onemocnění jater (silymarin v kombinaci)	p.o.	0.21	GM	5.51

11.8	A05BA03	silymarin	parent.	0.35	GM	2 345.13	H

11.9	A05BA03	silymarin (do 70 mg včetně v jedné tabletě)	p.o.	0.21	GM	5.51

01147	SILYMARIN AL 50	drg 100x50mg	APA	D
76762	SILYMARIN AL 50	drg 30x50mg	APA	D

11.10	A05BA03		silymarin (nad 70 mg v jedné tabletě)	p.o.	0.21	GM	4.40

12		laxativa a další léčiva k očištění střeva

12.1	A06AD10		kombinace minerálních solí (k přípravě Golytelyho roztoku)	p.o.	4.00	DF	242.70

12.2	A06AD11		laktulóza	p.o.	6.70	GM	4.50	L/GIT,INT,GER, PED,CHI, ONK

42547

LACTULOSE AL SIRUP

por sir 1x500ml

APA

12.3	A06AD12	laktitol	p.o.	10.00	GM	3.71	L/GIT,INT,GER, CHI

12.4	A06AD15	macrogol	p.o.	4.00	DF	242.70

12.5	A06AG10	sorbitol v kombinaci s kont. laxativem	p.rect.	2.00	DF	174.01

92489

YAL

sol 10x67.5ml

TRM

13		antidiarhoika, antiinfekční a protizánětlivá léčiva gastrointestinálního traktu, perorální podání

13.1	A07AA01		neomycin	p.o.	5.00	GM	609.91	H

13.2	A07AA02		nystatin	p.o.	1.50	MU	5.96

13.3	A07AA03		natamycin	p.o.	0.30	GM	41.01

13.4	A07AA11		rifaximin	p.o.	0.80	GM	85.00	P

Rifaximin is indicated for use in:

(1) hepatic encephalopathy,

2) prophylaxis in colorectal surgery,

3) pseudomembranose colitis,

4) bacterial infections associated with non-specific inflammatory bowel disease (Crohn 's disease and ulcerative colitis) susceptible to rifaximin,

5) Proven diverticulitis of the trachea susceptible to rifaximin.

13.5	A07BC05	diosmectit (plv. susp.)	p.o.	1.00	DF	3.86	L/PED, INF

13.6	A07EA06	budesonid	p.o.	9.00	MG	103.80	P

Treatment with oral budesonide is performed by a gastro-enterologist or an intern in an acute attack or chronic phase of Crohn 's disease, in particular where the need for steroid treatment occurs and the need to minimise their systemic effects.

64786	BUDENOFALK	cps ent 50x3mg	FAK	D
64787	BUDENOFALK	cps ent 100x3mg	FAK	D

13.7

A07EB01

natrium kromoglykát

p.o.

800.00

73.58

Treatment with cromoglycate is indicated by an allergologist and a clinical immunologist based on an allergological examination of skin possibly exposure tests or a specific IgE of antibodies, and with proven food allergy with severe local or overall symptoms that cannot be fully corrected by elimination of food allergens.

13.8

A07EC01

sulfasalazin

p.o.

2.00

15.14

L/GIT,INT,REV, GER

02159	SULFASALAZIN K	por tbl flm50x500mg	KRK	SLO
04304	SULFASALAZIN K-EN	por tblent100x500mg	KRK	SLO

13.9

A07EC02

mesalazin (léková forma - sáčky)

p.o.

1.50

44.12

Mesalazine per os - pharmaceutical forma-sachets: is an aminosalicylate of first choice for idiopathic intestinal inflammation (Crohn 's disease) affecting the upper part of the digestive tract, small intestine and adjacent parts of the colon (ileocolitis) in children under 3 years of age and in patients with swallowing disorder. It is not a first-choice aminosalicylate for the location of idiopathic intestinal inflammation in the colon; is indicated after failure of other aminosalicylates.

13.10

A07EC02

mesalazin (potahované tablety)

p.o.

1.50

23.08

L/GIT,INT,GER

75567	SALOFALK 500	tbl obdent100x500mg	FAK	D
93235	SALOFALK 250	tbl ent 100x250mg	FAK	D

13.11

A07EC02

mesalazin (tablety s řízeným uvolňováním)

p.o.

1.50

44.12

Mesalazine powder - modified-release tablets: is a first-choice aminosalicylate in idiopathic intestinal inflammation (Crohn 's disease) affecting the upper gastrointestinal tract, small intestine and adjacent colon (ileocolitis). It is not a first-choice aminosalicylate for the location of idiopathic intestinal inflammation in the colon, it is indicated here after failure of other aminosalicylates.

13.12

A07FA

protiprůjmové mikroorganismy (Escherichia coli), lékové formy tobolek

p.o.

2.00

25.14

The product is indicated for maintenance treatment in non-specific intestinal inflammation.

66065

MUTAFLOR 20MG

cps ent 20x20mg

ARP

13.13	A07FA	protiprůjmové mikroorganismy (Escherichia coli), tekuté lékové formy	p.o.	1.00	DF	43.99	L/PED, INF

13.14	A07FA01	organismy produkující kyselinu mléčnou, pevné lékové formy	p.o.	4.00	DF	3.86	L/PED,GIT,GER, INF

13.15	A07FA01	organismy produkující kyselinu mléčnou, tekuté lékové formy	p.o.	2.00	ML	3.55	L/PED,GIT,GER, INF

09159	HYLAK FORTE	sol 1x100ml			MCK	D
09158	HYLAK FORTE	sol 1x30ml			MCK	D

13.16

A07FA02

saccharomyces boulardii sicatus

p.o.

1.00

5.50

Preparations containing saccharomyces boulardii sicatus are indicated for the treatment of infectious diarrhoea, prophylaxis and treatment of diarrhoea in patients fed with gastric or enteral nutrition using a probe. They are not covered by public health insurance for prophylaxis and treatment of travellers' diarrhoea.

14		antidiarhoika, antiinfekční a protizánětlivá léčiva gastrointestinálního traktu, ostatní cesty aplikace

14.1	A07EA06		budesonid	p.rect.	2.00	MG	250.00	L/GIT,INT,GER

14.2	A07EC		paraaminosalicylát sodný	p.rect.	2.00	GM	46.20	L/GIT

14.3	A07EC02		mesalazin (čípky do 250 mg včetně)	p.rect.	1.50	GM	117.19	L/GIT

13489

SALOFALK 250

rct sup 30x250mg

FAK

14.4

A07EC02

mesalazin (čípky nad 250 mg)

p.rect.

1.50

101.11

L/GIT

75568	SALOFALK 500	sup 10x500mg	FAK	D
75569	SALOFALK 500	sup 30x500mg	FAK	D
76704	ASACOL	sup 20x500mg	TLT	CH

14.5

A07EC02

mesalazin (enm.)

p.rect.

1.50

68.28

L/GIT

93770

SALOFALK 4 GM

enm 7x60ml/4gm

FAK

15		digestiva včetně enzymových přípravků

15.1	A09AA		enzymové přípravky (s pankreatinem, dle obsahu lipázy)	p.o.	5 000.00	U	0.10

15.2	A09AA02		multienzymy (dle obsahu lipázy: do 10 000U včetně v jedné tabletě)	p.o.	5 000.00	U	0.10

15.3	A09AA02		multienzymy (dle obsahu lipázy: nad 10 000 do 19 999 U v jedné tabletě)	p.o.	5 000.00	U	0.10

15.4	A09AA02		multienzymy (dle obsahu lipázy: 20 000U v jedné tabletě)	p.o.	5 000.00	U	1.41	P

Multienzymes as gastro-resistant tablets containing 20,000 lipase They are indicated in patients with established algic form of chronic pancreatitis (evidence of evidence of ERCP or CT).

40379

PANZYNORM FORTE-N

por TBL FLM 100

KRK

SLO

15.5

A09AA02

multienzymy (dle obsahu lipázy: nad 20000U v jedné tabletě) – formy mikropelet

p.o.

5 000.00

1.95

Micropellet multienzymes are indicated in patients with cystic fibrosis and established chronic pancreatitis (evidence must be provided with an ERCP or CT).

54534

PANZYTRAT 25 000

por cps dur 50- sklo

NOA

15.6	A09AA02		multienzymy (dle lipázy, nad 20.000 U v jedné tabletě)	p.o.	5 000.00	U	0.10

15.7	A09AC01		pepsin a kyselinotvorné látky	p.o.	2.00	DF	0.10

16		insuliny krátkodobě působící

16.1	A10AB01		insulin lidský rychle účinkující 100 U/ml, cartridge	parent.	40.00	U	22.00	L/DIA

92608

HUMULIN R CARTIDGE

inj sol 5x3ml/300ut

LIL

16.2

A10AB01

insulin lidský rychle účinkující 100 U/ml, cartridge v jednorázovém aplikátoru

parent.

40.00

28.00

Diabetes mellitus treated with insulin in patients with defined visual impairment determined by ophthalmologist examination - a decrease in visual acuity below 0.4 on a better eye with optimal correction and at a value of visual acuity up to close of more than 10 Jg with optimal correction and proven not to use other applicators due to visual impairment.

16.3

A10AB01

insulin lidský rychle účinkující, lahv.

parent.

40.00

16.67

44576

HUMULIN R 100 M.J./ML

inj 1x10ml/1ku

LIL

16.4	A10AB03		insulin vepřový rychle účinkující - cartridge	parent.	40.00	U	22.00	L/DIA

16.5	A10AB03		insulin vepřový rychle účinkující - lahv.	parent.	40.00	U	16.48

17		insuliny střednědobě působící včetně kombinací

17.1	A10AC02		insulin hovězí středně dlouze účinkující -cartridge	parent.	40.00	U	21.60	L/DIA

17.2	A10AC02		insulin hovězí středně dlouze účinkující -lahv.	parent.	40.00	U	11.99

17.3	A10AC03		insulin vepřový středně dlouze účinkující	parent.	40.00	U	12.64

17.4	A10AC30		insulin kombinace zvířecí středně dlouze účinkující	parent.	40.00	U	12.64

17.5	A10AD01		insulin lidský kombinace středně a rychle účinného 100U/ml, cartridge	parent.	40.00	U	22.00	L/DIA

92605

HUMULIN M3 (30/70) CARTIDGE

inj sus 5x3ml/300ut

LIL

17.6

A10AD01

insulin lidský kombinace středně a rychle účinného 100U/ml, cartridge v jednorázovém aplikátoru

parent.

40.00

28.00

Diabetes mellitus treated with insulin in people with defined visual impairment determined by ophthalmologist examination - a decrease in visual acuity below 0.4 on a better eye with optimal correction and at a value of visual acuity up to 10 Jg with optimal correction and proven not to use other applicators due to visual impairment.

17.7

A10AD01

insulin lidský kombinace středně a rychle účinného, lahv.

parent.

40.00

16.67

40878

INSULIN-HM MIX 30

inj 1x10ml/1ku

LEX

18		insuliny dlouhodobě působící

18.1	A10AC01		insulin lidský středně dlouze účinkující 100U/ml, cartridge	parent.	40.00	U	22.00	L/DIA

92607

HUMULIN N (NPH) CARTIDGE

inj sus 5x3ml/300ut

LIL

18.2

A10AC01

insulin lidský středně dlouze účinkující 100U/ml, cartridge v jednorázovém aplikátoru

parent.

40.00

28.00

18.3

A10AC01

insulin lidský středně dlouze účinkující, lahv.

parent.

40.00

16.67

40875	INSULIN-HM NPH	inj 1x10ml/1ku	LEX	CZ
44567	HUMULIN N 100 M.J./ML	inj 1x10ml/1ku	LIL	F

18.4	A10AE01	insulin lidský dlouhodobě účinkující	parent.	40.00	U	16.67

18.5	A10AE02	insulin hovězí dlouhodobě účinkující -lahv.	parent.	40.00	U	11.99

18.6	A10AE30	insulin kombinace zvířecí dlouhodobě účinkující	parent.	40.00	U	12.64

18.7	A10AE04	insulin glargin, dlouhodobě účinný, lahv.	parent.	40.00	U	22.00	L/DIA

18.8	A10AE04	insulin glargin, dlouhodobě účinný, cartridge	parent.	40.00	U	49.00	P

18.9	A10AE05	insulin detemir, dlouhodobě účinný, cartridge	parent.	40.00	U	49.00	P

Long-acting insulin analogues are indicated only in patients treated with diabetes mellitus or outpatient diabetes mellitus on the recommendation of the diabetes centre for whom treatment with an insulin pump is indicated (repeated hypoglycaemia, unsatisfactory diabetes, requiring long-term effective insulin multiple times daily).

19		analoga insulinů a insuliny používané k aplikaci pomocí insulinové pumpy

19.1	A10AB04		insulin-lispro krátce působící, cartridge 100U/ML	parent.	40.00	U	30.49	P

19.2	A10AB04		insulin-lispro krátce působící, lahv.	parent.	40.00	U	28.28

19.3	A10AB05		insulin-aspart krátce působící, cartridge 100U/ML	parent.	40.00	U	30.49	P

19.4	A10AB05		insulin-aspart krátce působící, lahv.	parent.	40.00	U	28.28

19.5	A10AB06		insulin glulisin, cartridge 100U/ML	parent.	40.00	U	30.49	P

Insulins in cartridges (cartridge) are indicated in patients with diabetes mellitus of all types where compensation is not possible in any other way:

(a) adolescents under 18 years of age treated with two or more insulin daily,

(b) treated with intensive insulin at four or more doses;

(c) patients whose general health prevents insulin from being injected with a syringe (e. g. visual impairment, impotence, nervous system disease with trembling upper limbs).

Insulin analogues (insulin aspart, insulin lispro, insulin glulisine) are indicated in patients who lead to a demonstrable improvement in glycaemic control compared to conventional human insulin, i. e. where they make the mean HbA1c decrease by at least 10% and therefore lead to an improvement in glycaemic profiles, including a reduction in the frequency of hypoglycaemia.

19.6

A10AB01

insulin lidský rychle účinkující pro aplikaci do insulínových pump

parent.

40.00

28.24

L/DIA

28001	VELOSULIN 100 IU/ML	inj sol 1x10ml/1ku	NOO	DK
81496	VELOSULIN HM (GE)	inj sol1x10ml/100ut	NOO	DK

19.7	A10AD05	insulin aspart, kombinace středně a rychle účinného, cartridge	parent.	40.00	U	30.49	L/DIA

20	perorální antidiabetika ze skupiny biguanidů a glitazonů

20.1	A10BA02	metformin hydrochlorid	p.o.	2.00	GM	6.12

30356	METFORMIN AL 500	por tbl flm60x500mg	APA	D
41506	METFIREX 850 MG	por tblflm120x850mg	CHN	H

20.2	A10BA03	buformin	p.o.	0.20	GM	3.47

20.3	A10BD02	metformin a glibenklamid - kombinace	p.o.	3.00	DF	4.95

20.4	A10BD03	metformin a roziglitazon v kombinaci 500 mg a 1 mg	p.o.	1.00	DF	10.55	P

20.5	A10BD03	metformin a roziglitazon v kombinaci 500 mg a 2 mg	p.o.	1.00	DF	19.60	P

20.6	A10BD03	metformin a roziglitazon v kombinaci 1000 mg a 2 mg	p.o.	1.00	DF	21.10	P

Metformin and rosiglitazone in combination are indicated for the treatment of patients with type 2 diabetes and overweight (BMI greater than 25 kg / m2) and insufficient compensation for previous metformin therapy of at least 2 g daily (fasting glucose greater than 7,0 mmol / l, HbA1c greater than 6,0% / according to IFC /).

20.7	A10BF01	akarboza	p.o.	0.30	GM	10.26

20.8	A10BG02	rosiglitason s obsahem 4 mg v jedné tabletě	p.o.	1.00	DF	36.20	P

20.9	A10BG03	pioglitazon s obsahem 15 mg v jedné tabletě	p.o.	1.00	DF	32.00	P

20.10	A10BG03	pioglitazon s obsahem 30 mg v jedné tabletě	p.o.	1.00	DF	41.60	P

Thiazolidinedione derivatives are indicated for the treatment of patients with type 2 diabetes and overweight (BMI > 25 kg / m2) with expressed insulin resistance. They are indicated in combination with other PAD; in monotherapy only in contraindication or intolerance to metformin (diarrhoea, vomiting) and other PADs, under conditions of insufficient control by treatment to date (fasting glucose greater than 7,0 mmol, HbA1c greater than 6,0% / according to IFC /). The daily dose paid from public health insurance is 1 tbl (containing 4 mg) rosiglitazone or 1 tbl (containing 15 mg or 30 mg) pioglitazone.

21		perorální antidiabetika ze skupiny sulfonylurey a meglitinidů, případně další antidiabetika

21.1	A10BB01		glibenklamid (do 1 mg v jedné tabletě včetně)	p.o.	10.00	MG	2.30

21.2	A10BB01		glibenklamid (nad 1 mg v jedné tabletě)	p.o.	10.00	MG	0.86

21.3	A10BB01		glibenklamid (mikronizované formy, do 1,75 mg včetně v jedné tabletě)	p.o.	7.00	MG	1.37

94523

GLUCOBENE 1.75 MG

tbl 120x1.75mg

MCK

21.4

A10BB01

glibenklamid (mikronizované formy, nad 1,75 mg v jedné tabletě)

p.o.

7.00

0.86

94525

GLUCOBENE 3.5 MG

tbl 120x3.5mg

MCK

21.5	A10BB02	chlorpropamid	p.o.	0.37	GM	0.78

21.6	A10BB03	tolbutamid	p.o.	1.50	GM	2.32

21.7	A10BB04	glibornurid	p.o.	38.00	MG	4.79

21.8	A10BB05	tolazamid	p.o.	1.00	GM	2.49

21.9	A10BB07	glipizid	p.o.	10.00	MG	3.80

87110

ANTIDIAB

tbl 30x5mg

KRK

SLO

21.10	A10BB08		gliquidon	p.o.	60.00	MG	5.65

21.11	A10BB09		gliklazid	p.o.	0.16	GM	5.90

21.12	A10BB09		gliklazid, retardované lékové formy	p.o.	2.00	DF	5.90

21.13	A10BB12		glymepirid do 2 mg v jedné tabletě včetně	p.o.	2.00	MG	5.90

21.14	A10BB12		glymepirid nad 2 mg v jedné tabletě	p.o.	2.00	MG	4.90

21.15	A10BX02		repaglinid	p.o.	1.00	DF	5.00	L/DIA

21.16	A10BX03		nateglinid	p.o.	1.00	DF	5.00	L/DIA

22		vitamin A nebo D včetně jejich kombinací, perorální podání

22.1	A11CA01		retinol (vitamin A)	p.o.	50.00	KU	1.12

22.2	A11CC01		ergocalciferol (pevné lékové formy)	p.o.	6.00	KU	0.54

00353

VITAMIN D SLOVAKOFARMA

cps 1x300ku

SLO

22.3	A11CC01	ergokalciferol (tekuté lékové formy, do 200 U/ml včetně)	p.o.	6.00	KU	13.10

22.4	A11CC01	ergokalciferol (tekuté lékové formy, nad 200 U/ml)	p.o.	6.00	KU	0.78

00716

INFADIN

gtt 1x10ml/100mg

SLO

22.5	A11CC02	dihydrotachysterol	p.o.	1.00	MG	17.13

22.6	A11CC03	alfakalcidol do 0,50 rg včetně	p.o.	1.00	RG	18.60	P

22.7	A11CC03	alfakalcidol nad 0,50 rg	p.o.	1.00	RG	17.55	P

22.8	A11CC04	kalcitriol	p.o.	1.00	RG	35.10	P

Treatment with alfacalcidol and calcitriol is indicated by an internist, an endocrinologist, a urologist, a pediatrician and a physician in a dialysis unit in patients:

1. With osteoporosis:

(a) a senile or osteoporotic fracture which has developed during vitamin D and calcium-free therapy;

(b) induced by the treatment of glucocorticoids,

(c) at a high dose of corticosteroids (7,5 mg prednisone daily and greater) with elevated PTH levels resistant to vitamin D and calcium therapy.

2. For the treatment of renal osteodystrophy with chronic renal insufficiency (particularly in patients on dialysis).

3. With vitamin D resistance.

4. Vitamin D resistant osteomalacia.

5. With hypoparathyroidism or pseudo-hypoparathyroidism resistant to vitamin D and calcium treatment.

22.9	A11CC05	cholekalciferol - pevné lékové formy	p.o.	0.50	MG	1.04

22.10	A11CC05	cholekalciferol – tekuté lékové formy	p.o.	0.50	MG	3.84

12023

VIGANTOL

por gtt sol 1x10ml

MEC

23		vitamin A nebo D včetně jejich kombinací, ostatní cesty aplikace

23.1	A11CA01		retinol (vitamin A)	parent.	50.00	KU	10.40

23.2	A11CC		paricalcitolum	parent.	2.50	RG	385.00	O/P

Paricalcitol treatment is indicated if:

(a) the serum PHT concentration is greater than 400pg / ml despite treatment with calcitriol for 3 months;

(b) calcitriol (hypercalcaemia for calcitiol - greater than 2,7 mmol / l and hyperphosphatemia greater than 2,5 mmol / l; phosphocalcatic product greater than 6,5) fails,

The treatment condition is:

(a) sonographically proven enlarged parathyroid organs,

(b) verified hemodialysis efficacy (Kt / V above 1,2);

(c) the compliance of the patient with measures regulating serum phosphorus concentrations (dietotherapy, effective dialysis, phosphate binders in GIT).

23.3	A11CC01	ergokalciferol	parent.	6.00	KU	0.72

23.4	A11CC04	kalcitriol	parent.	1.00	RG	174.20	P

Treatment with parenteral calcitriol, is performed by an internist, an endocrinologist, a urologist, a pediatrician and a physician in the dialysis unit in patients:

1. With osteoporosis:

(a) a senile or osteoporotic fracture which has developed during vitamin D and calcium-free therapy;

(b) induced by the treatment of glucocorticoids,

(c) at a high dose of corticosteroids (7,5 mg prednisone daily and greater) with elevated PTH levels resistant to vitamin D and calcium therapy.

2. For the treatment of renal osteodystrophy with chronic renal insufficiency (particularly in patients on dialysis).

3. With vitamin D resistance.

4. Vitamin D resistant osteomalacia.

5. With vitamin D and calcium-resistant hypoparathyroidism.

23.5

A11CC05

cholekalciferol

parent.

1.00

0.94

11093

VIGANTOL 50000

inj 5x1ml/1.25mg

MEC

24		soli vápníku, perorální podání

24.1	A12AA03		glukonát vápenatý (na obsah vápníku)	p.o.	0.50	GM	0.59

24.2	A12AA04		uhličitan vápenatý (na obsah vápníku) tablety	p.o.	0.50	GM	2.34

70536

TBL.CALCII CARBON.PRAEC.0.5 MVM

portblnob1000x0.5gm

MVM

24.3	A12AA04		uhličitan vápenatý (na obsah vápníku), léková forma šumivé tablety	p.o.	0.50	GM	2.34

24.4	A12AA04		uhličitan vápenatý(na obsah vápníku), léková forma prášky	p.o.	0.50	GM	2.34

24.5	A12AA07		chlorid vápenatý (na obsah vápníku), tekuté lékové formy,	p.o.	0.20	GM	0.64

24.6	A12AA12		octan vápenatý (na obsah vápníku)	p.o.	0.50	GM	10.00

25		kombinace solí vápníku, perorální podání

25.1	A12AA20		vápník (kombinace různých solí, na obsah vápníku)	p.o.	0.50	GM	2.54

25.2	A12AX		uhličitan vápenatý v kombinaci s cholekalciferolem (na obsah vápníku) do 600 mg vápníku v 1 dávce včetně a do 5 mg cholekalciferolu v 1 dávce včetně	p.o.	1.00	DF	3.26

25.3	A12AX		uhličitan vápenatý v kombinaci s cholekalciferolem (na obsah vápníku) do 600 mg vápníku v 1 dávce včetně a nad 5 mg cholekalciferolu v 1 dávce	p.o.	1.00	DF	4.00

25.4	A12AX		uhličitan vápenatý v kombinaci s cholekalciferolem (na obsah vápníku) nad 600 mg vápníku v 1 dávce	p.o.	1.00	DF	6.51

25.5	A12AX		vápník v kombinaci s fluorem (fluorofosfat sodný)	p.o.	1.00	DF	5.38	L/INT,GYN,ORT, REV,GER

25.6	A12AX		vápník v kombinaci s fluorem (levoglutamid fluorofosfat)	p.o.	1.00	DF	4.01	L/INT,GYN,ORT, REV,GER

25.7	A12CX		jiné minerální produkty (na obsah vápníku)	p.o.	0.50	GM	1.19

99808

BIOMIN H

plv 60x3gm(sáčky)

BMN

26		soli vápníku, ostatní cesty aplikace

26.1	A12AA03		glukonát vápenatý (na obsah vápníku)	parent.	3.00	GM	59.16

26.2	A12AA07		chlorid vápenatý (na obsah vápníku)	parent.	0.20	GM	2.98

00409

CALCIUM CHLORATUM BIOTIKA

inj 5x10ml 10%

HBS

27		soli draslíku, perorální podání

27.1	A12BA		draslík (na obsah draslíku)	p.o.	1.50	GM	2.44

27.2	A12BA		draslík v kombinaci s hořčíkem (na obsah draslíku)	p.o.	1.00	GM	9.78

27.3	A12BA01		chlorid draselný (na obsah chloridu draselného)	p.o.	3.00	GM	2.37

13715

KALNORMIN

por tbl pro 30x1gm

ICN

28		soli draslíku, ostatní cesty aplikace

28.1	A12BA		draslík v kombinaci s hořčíkem	parent.	1.00	DF	13.20	O

02132

CARDILAN

inj 10x10ml

HBS

28.2	A12BA	draslík v kombinaci s hořčíkem, léková forma infuzí	parent.	250.00	ML	86.00	O

28.3	A12BA01	chlorid draselný (na obsah chloridu draselného)	parent.	3.00	GM	53.45	O

02486

KALIUM CHLORATUM LÉČIVA 7.5%

inj 5x10ml 7.5%

LEX

29		soli hořčíku a jiné minerální produkty, perorální podání

29.1	A12CC03		glukonat hořečnatý (na obsah hořčíku)	p.o.	1.00	GM	11.38	L/INT,NEU,PSY, GYN,GER

29.2	A12CC04		citronan hořečnatý (na obsah hořčíku)	p.o.	1.00	GM	11.38	L/INT,NEU,PSY, GYN,GER

29.3	A12CC05		aspartat hořečnatý (na obsah hořčíku)	p.o.	1.00	GM	11.38	L/INT,NEU,PSY, GYN,GER

29.4	A12CC06		mléčnan hořečnatý (na obsah hořčíku)	p.o.	1.00	GM	11.38	L/INT,NEU,PSY, GYN,GER

29.5	A12CC09		orotat hořečnatý (na obsah hořčíku)	p.o.	1.00	GM	11.38	L/INT,NEU,PSY, GYN,GER

29.6	A12CC30		kombinace hořečnatých solí (na obsah hořčíku)	p.o.	1.00	GM	11.38	L/INT,NEU,PSY, GYN,GER

99891

MAGNESIUM 250 MG PHARMAVIT

por tbl eff 20

CPW

30		soli hořčíku, ostatní cesty aplikace

30.1	A12CC02		síran hořečnatý (koncentrace do 10 % včetně)	parent.	1.00	GM	19.72	O

30.2	A12CC02		síran hořečnatý (koncentrace nad 10%)	parent.	1.00	GM	9.28	O

00499

MAGNESIUM SULFURICUM BIOT.20%

inj 5x10ml 20%

HBS

31		soli fluoru, perorální podání

31.1	A12CD01		fluorid sodný	p.o.	88.00	MG	4.06

09495

OSSIN RETARD

tbl obd 100x40mg

GRU

32		ostatní léčiva ovlivňující trávicí systém

32.1	A08AA10		sibutramin s obsahem 10 mg v jedné tabletě	p.o.	15.00	MG	90.80	P

32.2	A08AA10		sibutramin s obsahem 15 mg v jedné tabletě	p.o.	15.00	MG	68.40	P

Sibutramine prescribes diabetic patients with inadequately compensated type 2 diabetes mellitus (glycohaemoglobin > 6% / according to IFC /) and at the same time with BMI > 35 kg / m2 who are diagnosed with diabetic dyslipidaemia requiring pharmacological treatment. The contraindication is ICHS or blood pressure above 145 / 90. Sibutramine can only be prescribed to patients who reduce their weight by 3 kg over a 6-week period using only the regimen (diet and motion) measures. Tolerance should be evaluated every 14 days after initiation of therapy (blood pressure and heart rate) for 3 months, efficacy after 3 months of treatment with sibutramine. Efficacy criteria for sibutramine therapy are a weight decrease of at least 5% of baseline body weight while improving glycaemic control (fasting glucose or a decrease of at least 0,5% of HbA1c). If treatment is not effective, sibutramine is discontinued after 3 months. Sibutramine therapy is indicated for a maximum of 12 months.

32.3

A08AB01

orlistat

p.o.

360.00

68.40

Diabetologist indicates orlistat for the treatment of obese type 2 and BMI patients above 35 kg / m2 with concurrently diagnosed arterial hypertension and / or dyslipidaemia and / or ischaemic heart disease in whom diabetes is not satisfactorily compensated (HbA1c greater than 6.0% / IFC /) with existing antidiabetic medication. Efficacy of orlistat therapy is checked after 3 months, the criterion being improved glycaemic control (fasting glucose or a decrease in HbA1c of at least 0,5% in absolute terms) and weight decrease of at least 5% of baseline body weight. If treatment is not effective, administration of orlistat is discontinued after 3 months. Treatment is indicated for a maximum of 12 months.

32.4	A11GA01	kyselina askorbová (vitamin C)	parent.	0.20	GM	3.32	H

32.5	A14AB01	nandrolon phenpropionát	parent.	2.00	MG	3.11

32.6	A16AA01	levokarnitin	parent.	2.00	GM	356.82	O

32.7	A16AA02	ademetionin	p.o.	1.00	GM	59.83	Z

32.8	A16AA02	ademetionin	parent.	0.50	GM	94.66	Z

12319

TRANSMETIL 500 MG INJEKCE

inj pso Iqf 5x500mg

HOL

32.9	A16AB02	imiglucerasa	parent.	200.00	U	40 341.80	Z

32.10	A16AB03	agalsidáza alfa	parent.	1.00	MG	17 700.00	Z

32.11	A16AB04	agalsidáza beta	parent.	5.00	MG	17 700.00	Z

32.12	A16AB05	laronidáza	parent.	1.00	DF	33 264.00	Z

13206	ALDURAZYME	inf cnc sol 1x5ml	GBZ	GB
13207	ALDURAZYME	inf cnc sol 10x5ml	GBZ	GB
13208	ALDURAZYME	inf cnc sol 25x5ml	GBZ	GB

32.13

A16AX01

kyselina tioktová

parent.

0.20

81.09

55380	THIOGAMMA 600 INJECT	inj 20x20ml/600mg	SLH	D
84378	THIOGAMMA 600 INJECT	inj 5x20ml/600mg	SLH	D
84379	THIOGAMMA 600 INJECT	inj 10x20ml/600mg	SLH	D
55381	THIOGAMMA 600 INJECT	inj 500x20ml/600mg	SLH	D
84380	THIOGAMMA 600 INJECT	inj 50x20ml/600mg	SLH	D
84381	THIOGAMMA 600 INJECT	inj 100x20ml/600mg	SLH	D
84382	THIOGAMMA 600 INJECT	inj 1000x20ml/600mg	SLH	D

Zobrazit všechna ustanovení (1662)

Čl. I Čl. II Čl. III

Comments 0

To write comments, please sign in.

Regulation Information

Citation	Decree No. 225 / 2005 Coll., amending Decree No. 589 / 2004 Coll., on the reimbursement of medicines and foodstuffs for special medical purposes
Regulation Type	Order
Author	-
Collection	Code of Laws

Date of Promulgation	15.06.2005
Effective from	01.07.2005
Effective until	-
Status	Valid

Legal Areas: Civil law Civil law substantive Administrative law Health

The regulation text is for informational purposes only.

Decree No. 225 / 2005 Coll.

Decree amending Decree No. 589 / 2004 Coll., on the reimbursement of medicines and foodstuffs for special medical purposes

Contents

Čl. I

Příloha č.1

Contents

Comments 0

Regulation Information

Partner Websites

Favorites

Browsing History